All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
It has been announced that fedratinib, a pyrimidine-based Janus kinase 2 (JAK2) inhibitor, has been granted approval by Health Canada for the treatment of adult patients who have a large spleen size and show symptoms due to intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF. The approval was based on favorable results of phase III JAKARTA and JAKARTA2 trials.
Fedratinib had been previously approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with intermediate-2 or high-risk primary or secondary MF in August 2019, and its marketing authorization status is currently being assessed by the European Medicines Agency (EMA).
The MPN Hub has provided a summary of the long drug development journey of fedratinib here.
Is pacritinib safe and efficacious for patients with MF who failed ruxolitinib?
The MPN Hub were pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US, during the 61st American Society of Hematology (ASH) meeting...
Fedratinib in myelofibrosis
Fedratinib is a pyrimidine-based Janus kinase 2 (JAK2) inhibitor currently licenced by the U.S. Food and Drug Administration (FDA) for the treatment of adults with intermediate-2 or high-risk primary or secondary...
Subscribe to get the best content related to MPN delivered to your inbox